Article Sidebar

Submitted
Apr 22, 2021
Published
Apr 22, 2021
Download
PDF
Statistic
Read Counter : 41 Download : 32

Main Article Content

Abstract

Proteus syndrome is a very complex and rare to find in world. It consists asymmetric and disproportionate overgrowth in bones and skins. There are very few cases that have been come in light all over the world such as 1 over 1 million. The drug designing is the inventive process of finding new medications based on the knowledge of a biological target. It also involves the design of small molecules that are complementary in shape and charge to the bimolecular target with which they interact and therefore will bind to it. Proteus syndrome is caused by AKT1 and PTEN genes. The PTEN gene is taken for the modeling and research. It consists 403 amino acids and it acts as a tumor suppressor. Proteus syndrome is not a disease but a disorder. It is related to the PI3K-AKT Signaling Pathway which eventually led to the clinical approaches as their effect. So that, the structure based molecular expression and modeling can be taken to a direction and lead to the mainly drug designing for the welfare of the suffering persons of this syndrome.

Keywords

Proteus Syndrome PTEN

Article Details

How to Cite
Ayushi Arya, Ved Kumar Mishra, Naveen Dwivedi, Shubha Dwivedi, Prashant Ankur Jain, & Amit Tiwari. (2021). In silico structure based molecular expression and modeling of PTEN gene for proteus syndrome. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(3), 302-313. https://doi.org/10.61096/ijrpp.v4.iss3.2015.302-313
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Cohen MM Jr, Hayden PW (1997). A newly recognized hamartomatous syndrome. Birth Defects Orig Art Ser, 15(5B): 291–296.
  2. [2]. Wiedemann HR, Burgio GR, Aldenhoff P, Kunze J, Kaufmann HJ, Schilk E (1983). The Proteus syndrome: partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skull anomalies and possible accelerated growth and visceralaffections. Eur J Pediat, 140: 5–12.
  3. [3]. Cohen MM Jr (1988). Understanding Proteus syndrome: Unmasking the elephant man and stemming elephant fever. Neurofibromatosis, 1:260–280.
  4. [4]. Chothia, C; Lesk, AM (1986). "The relation between the divergence of sequence and structure in proteins". EMBO J 5 (4): 823–6. PMC 1166865. PMID 3709526
  5. [5]. Kaczanowski, S; Zielenkiewicz, P (2010). "Why similar protein sequences encode similar three-dimensional structures?” Theoretical Chemistry Accounts 125: 643–50.Doi: 10.1007/s00214-009-0656-3.
  6. [6]. Marti-Renom, MA; Stuart, AC; Fiser, A; Sanchez, R; Melo, F; Sali, A. (2000). "Comparative protein structure modeling of genes and genomes". Annu Rev Biophys Biomol Struct 29: 291–325. Doi:10.1146/annurev.biophys.29.1.291. PMID 10940251
  7. [7]. Chung SY, Subbiah S. (1996.) A structural explanation for the twilight zone of protein sequence homology. Structure 4: 1123–27.
  8. [8]. Williamson AR (2000). "Creating a structural genomics consortium". Nat Struct Biol 7(S1(11s)): 953
  9. [9]. Venclovas C, Margeleviĉius M (2005). "Comparative modeling in CASP6 using consensus approach to template selection, sequence-structure alignment, and structure assessment". Proteins 61 (S7): 99–105. doi:10.1002/prot.20725.
  10. [10]. Ramachandran K. I., G. Deepa, K. Namboori “Computational Chemistry and Molecular Modeling-Principles and Applications” a book, published in 2008 in Spinger publications.
  11. [11]. CohenMMJr, Hayden PW. A newly recognized hamartomatous syndrome. Birth Defects Orig Artic Ser 1979; 15:291–296
  12. [12]. Levine C. The imaging of body asymmetry and hemihypertrophy. Crit Rev Diagn Imaging 1990; 31:1–80.
  13. [13]. Hamm H. Cutaneous mosaicism of lethal mutations. Am J Med Genet 1999; 85:342–345.
  14. [14]. Steck P, Pershouse M, Jasser S, Yung W, Lin H, Ligon A et al. (Apr 1997). "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers". Nature Genetics 15 (4): 356–62. doi:10.1038/ng0497-356. PMID 9090379
  15. [15]. "OrthoMaM phylogenetic marker: PTEN coding sequence"
  16. [16]. "Entrez Gene: PTEN phosphatase and tensin homolog (mutated in multiple advanced cancers 1)".
  17. [17]. Chu E, Tarnawski A (Oct 2004). "PTEN regulatory functions in tumor suppression and cell biology". Medical Science Monitor 10 (10): RA235–41. PMID 15448614.
  18. [18]. Haynie D, Xue B (Feb 2015). "Superdomains in the protein structure hierarchy: The case of PTP-C2". Protein Science. doi:10.1002/pro.2664. PMID 25694109.
  19. [19]. Chen Z, Trotman L, Shaffer D, Lin H, Dotan Z, Niki M et al. (Aug 2005). "Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient
  20. [20]. Pilarski R, Eng C (May 2004). "Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome". Journal of Medical Genetics 41 (5): 323doi:10.1136/jmg.2004.018036 PMC 1735782 PMID 15121767 tumorigenesis". Nature 436 (7051):725–730. doi:10.1038/nature03918. PMC 1939938. PMID 16079851.
  21. [21]. Napoli E, Ross-Inta C, Wong S, Hung C, Fujisawa Y, Sakaguchi D et al. (2012). Bai Y, ed. "Mitochondrial dysfunction in Pten haplo-insufficient mice with social deficits and repetitive behavior: interplay between Pten and p53". PloS One 7 (8): e42504.doi:10.1371/journal.pone.0042504. PMC 3416855. PMID 22900024
  22. [22]. "Rodent of the Week: Nerves regenerated after spinal cord injury". The Los Angeles Times. August 13, 2010.
  23. [23]. Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A. 1998; 95:15406-11. PDB 1d5r;
  24. [24]. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP (October 1999). "Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association". Cell 99 (3): 323–34. doi:10.1016/S0092-8674(00)81663-3.PMID 10555148.
  25. [25]. Cohen M. M. Jr. and J. A. R. Tibbles The Proteus syndrome: the Elephant Man diagnosed 1986.
  26. [26]. Wiedemann HR, Burgio GR, Aldenhoff P, Kunze J, Kaufmann HJ, Schirg E: The proteus syndrome. Partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skull anomalies and possible accelerated growth and visceral affections. Eur J Pediatr 1983; 140: 5–12.
  27. [27]. Smith JM, Kirk EP, Theodosopoulos G, Marshall GM, Walker J, Rogers M, Field M, Brereton JJ, Marsh DJ (2002). "Germline mutation of the tumour suppressor PTEN in Proteus syndrome". J. Med. Genet. 39 (12): 937–
  28. [28]. Cardoso MT, de Carvalho TB, Casulari LA, Ferrari I (2003). "Proteus syndrome and somatic mosaicism of the chromosome 16". Panminerva medica 45 (4): 267–71.PMID 15206168
  29. [29]. Lipman, DJ; Pearson, WR (1985). "Rapid and sensitive protein similarity searches". Science 227 (4693): 1435–41. doi:10.1126/science.2983426. PMID 2983426.
  30. [30]. Altschul, Stephen; Gish, Warren; Miller, Webb; Myers, Eugene; Lipman, David (1990). "Basic local alignment search tool". Journal of Molecular Biology 215 (3): 403–410. doi:10.1016/S0022-2836(05)80360-2. PMID 2231712.
  31. [31]. Soding Johannes, Biegert Andreas and Lupas Andrei N. (2005).”The HHpred interactive server for protein homology detection and structure prediction” Nucleic Acids Res. 2005 Jul 1; 33(Web Server issue): W244–W248.
  32. [32]. Marsh DJ, Trahair TN, Martin JL, Chee WY, Walker J, Kirk EP, Baxter RC, Marshall GM (April 22, 2008). "Rapamycin treatment for a child with germline PTEN mutation". Nature Clinical Practice Oncology 5 (6): 357–361. doi:10.1038/ncponc1112. PMID 18431376
  33. [33]. Pritchard DI (2005). "Sourcing a chemical succession for cyclosporin from parasites and human pathogens". Drug Discovery Today 10 (10): 688–691. doi:10.1016/S1359-6446(05)03395-7. PMID 15896681
  34. [34]. Findlay, J.A. and Radics, L. Canadian J. Chem. 58, 579, (1980).
  35. [35]. Hughes, P. et al. Tetrahedron Letters, 33, 4739, (1992).
  36. [36]. Deléage G1, Blanchet C and Geourjon C (1997) “Protein structure prediction. Implications for the biologist” Biochimie. 1997 Nov;79(11):681-6.
  37. [37]. Geourjon C and Deléage G1 (1995) “SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments” Comput Appl Biosci. 1995 Dec; 11(6):681-4.
  38. [38]. Söding J (2005). "Protein homology detection by HMM-HMM comparison”. Bioinformatics 21 (7): 951–960.doi:10.1093/bioinformatics/bti125. PMID 15531603
  39. [39]. Söding J, Biegert A, Lupas AN (2005). "The HHpred interactive server for protein homology detection and structure prediction". Nucleic Acids Research 33 ((Web Server issue)): W244–248. doi:10.1093/nar/gki408. PMC 1160169. PMID 15980461
  40. [40]. Jörg Schultz, Frank Milpetz, Peer Bork, and Chris P. Ponting, (1998) “SMART, a simple modular architecture research tool: Identification of signaling domains” Proc. Natl. Acad. Sci. USA Vol. 95, pp. 5857–5864, May 1998 Colloquium Paper.
  41. [41]. Leo A, Hansch C, Elkins D (1971). "Partition coefficients and their uses". Chem Rev 71(6): 525–616. doi:10.1021/cr60274a001.
  42. [42]. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (March 2001). "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings". Adv. Drug Deliv. Rev. 46 (1-3): 3–26. doi:10.1016/S0169-409X(00)00129-0. PMID 11259830
  43. [43]. Lipinski CA (December 2004). "Lead- and drug-like compounds: the rule-of-five revolution". Drug Discovery Today: Technologies 1 (4): 337–341.doi:10.1016/j.ddtec.2004.11.007
  44. [44]. Orengo CA, Michie AD, Jones S, Jones DT, Swindells MB, Thornton JM (1997). "CATH--a hierarchic classification of protein domain structures". Structure 5 (8): 1093–1108. doi:10.1016/S0969-2126(97)00260-8. PMID 9309224.
  45. [45]. Chou P. and Fasman,G. (1978) Prediction of the secondary structure of proteins from their amino acid sequence. Adv. Enzymol. Relat. Areas Mol. Biol., 47, 45–148. [PubMed]
  46. [46]. Wampler J. (1997) Distribution analysis of the variation of B-factors of X-ray crystal structures; temperature and structural variations in lysozyme. J. Chem. Inf. Comput. Sci., 37, 1171–1180. [PubMed]
  47. [47]. Rune Linding, Robert B. Russell, Victor Neduva, and Toby J. Gibson (2003) “GlobPlot: exploring protein sequences for globularity and disorder” Nucleic Acids Res. 2003 Jul 1; 31(13): 3701–3708. PMCID: PMC169197